Article Text


PWE-108 Toxin A-specific antigen-activated and memory B cells in the circulation of patients with Clostridium difficile infection
  1. T M Monaghan,
  2. A Robins,
  3. H F Sewell,
  4. Y R Mahida
  1. Institute of Infection, Immunity & Inflammation, University of Nottingham, Nottingham, UK


Introduction In Clostridium difficile infection, antibody-mediated immune response to secreted toxins A and B (which are also the main virulence factors) appears to be important in determining the nature of clinical disease. During a bacterial infection, activation of B cells leads to loss of immunoglobulin (Ig) D and expression of antigen-specific Ig on the cell surface. Following resolution of infection, antigen-specific memory B cells may be detectable in the circulation. Our aim was to identify circulating toxin A-activated B cells during clinical disease and toxin A-specific memory B cells following resolution of C difficile infection.

Methods Purified C difficile toxin A was labelled with Alexa Fluor 488 (toxin A488) and its biological activity and specificity of fluorescence were confirmed using Vero cells and anti-toxin A antibody, respectively. Peripheral blood mononuclear cells (PBMNCs) were obtained from 20 patients [13 female, 7 male; median age 67 yrs (range 32–96 yrs)] with C difficile infection, within 10 days of diarrhoeal onset. For flow cytometry, PBMNCs were incubated on ice in the dark for 1 h in the absence or presence of toxin A488. After washing, cells were labelled with anti-CD19-ECD (B cell marker) and anti-IgD-PE (to identify antigen-activated IgD-negativecells). PBMNCs were also polyclonally stimulated in vitro for 6 days to induce differentiation of memory B cells to antibody secreting cells (ASCs). Enzyme-linked immunospot (ELISPOT) assays were used to quantify toxin A-specific IgG ASCs and expressed as percentage of total IgG ASCs. Toxin A-specific IgG antibody levels in sera were studied by ELISA. Data are expressed as median (range).

Results Compared to control buffer, a significantly greater proportion of events (flow cytometry) were seen in the CD19-positive, IgD-negative gate in PBMNCs exposed to toxin A488 [0.09% (0%–0.54%) vs 0.92% (0.09%–1.78%); p<0.001]. In four patients studied at the same time as flow cytometry, toxin A-specific ASCs were detected by ELISPOT assays (0.04%–2%). In studies over 4 (1–10) months after infection, toxin A-specific ASCs were observed [0.33 (0.07–2.12)%]. Serum anti-toxin A antibodies were detectable in eight patients at the time of clinical disease and in four patients, the antibody levels increased over the following 6 (2–10) months.

Conclusion (1) A small population of toxin A-specific, antigen-activated B cells can be detected in the circulation soon after C difficile infection. (2) In addition to circulating antibody, toxin A-specific memory B cells can be detected over many months after C difficile infection. (3) Future studies can investigate the relationship between the development of B cell responses to C difficile toxins and the nature of clinical disease.

Competing interests None declared.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.